What are the recommended first‑line and second‑line pharmacologic treatments for pediatric heart failure, including dosing, monitoring, and comparative efficacy?

Pharmacologic Treatment of Pediatric Heart Failure

Loop diuretics (furosemide 0.5-1 mg/kg IV/PO every 6-12 hours) are the first-line therapy for symptomatic pediatric heart failure with congestion, followed by sequential addition of ACE inhibitors, β-blockers, and aldosterone antagonists based on symptom severity and ventricular function. 1

First-Line Therapy: Diuretics

Loop diuretics are the cornerstone of initial management for children presenting with fluid overload and congestion 1. Furosemide is recommended at 0.5-1 mg/kg IV or orally every 6-12 hours, with the goal of achieving euvolemia over days to weeks 1.

Key monitoring requirements:

• Blood pressure, electrolytes (particularly potassium and sodium), and renal function
• Fluid restriction to 80% of basal metabolic requirements may be necessary
• For diuretic-resistant cases, add metolazone (thiazide class effect), but monitor closely for hypokalemia and hyponatremia 1

Critical pitfall: Indiscriminate IV fluid resuscitation is contraindicated and will worsen heart failure 1.

Second-Line: ACE Inhibitors

ACE inhibitors should be initiated after diuretic therapy in children with mild to moderate symptoms (NYHA/Ross class II-III) 1. The evidence base for ACE inhibitors in pediatric heart failure is moderate, though largely extrapolated from adult data 1.

Dosing considerations:

• Start low and titrate gradually
• Monitor blood pressure and renal function
• Reassess response at 1-2 week intervals initially 1

Third-Line: β-Blockers

β-blockers (carvedilol, metoprolol, or bisoprolol) are recommended for moderate to severe systolic dysfunction of the systemic left ventricle, particularly when ejection fraction remains <40% despite ACE inhibitor therapy 1.

Important nuances:

• Carvedilol dosing in children <4 years requires every 8-hour administration due to pharmacokinetics (vs. every 12 hours in older children) 1
• A large pediatric RCT (161 patients) failed to show improvement in composite clinical outcomes with carvedilol, though ejection fraction improved 1
• The study was underpowered and included heterogeneous populations (single ventricle, systemic right ventricle), which may have obscured benefits in dilated cardiomyopathy 1
• Exercise caution when initiating β-blockers after inotropic support 1

Fourth-Line: Aldosterone Antagonists

Spironolactone (starting dose 1 mg/kg/day, target maximum 2 mg/kg/day) is reserved for patients who fail to improve with ACE inhibitor and β-blocker therapy 1.

Critical monitoring:

• Check potassium and renal function before starting, at 7-14 days, and periodically thereafter
• Re-evaluate any potassium supplementation (high risk of hyperkalemia when combined with ACE inhibitors, especially with renal impairment)
• Male gynecomastia is a nonreversible complication requiring close monitoring 1

Acute Decompensated Heart Failure: Inotropic Support

For children presenting with underperfusion (poor perfusion, decreased urine output, cool extremities) in addition to congestion:

Milrinone is the preferred inotrope with vasodilatory properties that can increase cardiac index and reduce systemic vascular resistance 1. Use with caution in hypotensive patients due to peripheral dilation 1.

Catecholaminergic drugs (dopamine, dobutamine, epinephrine, norepinephrine) are alternatives but carry higher risks of arrhythmias, compromised distal perfusion, and increased myocardial oxygen demand 1.

Critical limitation: Inotropes are reserved for the sickest patients with genuine low cardiac output, organ dysfunction, and metabolic acidosis 1. They bridge to mechanical support or transplantation but have significant toxicities. If inotropic support is required for >48 hours, develop a plan for weaning, transition to mechanical support, or transplant evaluation 1.

Drugs NOT Recommended

Digoxin: No pediatric data support routine use in children with structurally normal hearts and systolic dysfunction 1. In adults, digoxin decreased hospitalization but not mortality 1. It does not improve contractility or symptoms in infants with large VSDs and pulmonary congestion 1.

Vasopressin antagonists (tolvaptan, conivaptan): Insufficient pediatric data; no survival benefit demonstrated in adults 1.

Sequential Treatment Algorithm

The Canadian Cardiovascular Society provides a symptom-based stepwise approach 1:

1. Mild symptoms (NYHA/Ross II): Pulsed diuretic therapy
2. Moderate symptoms (NYHA/Ross III): Add ACE inhibitor
3. Persistent dysfunction despite ACE inhibitor: Add β-blocker
4. Refractory to triple therapy: Add aldosterone antagonist
5. Severe/intractable symptoms (NYHA/Ross IV): Consider IV inotropic therapy, mechanical support, or transplant evaluation

The evidence base remains limited with most recommendations graded as moderate-quality evidence at best 1. Newer therapies like ARNIs and SGLT2 inhibitors show promise but require more pediatric-specific data 2, 3, 4, 5.